ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In particular, treatment of chronic myelogenous leukemia cell lines driven by the BCR-ABL chimeric oncogene with a BCR-ABL inhibitor promoted the activation of FOXO3a-dependent Bim expression, resulting in apoptosis [52].